Castle Biosciences, Inc. — Company profile
Healthcare · Diagnostics & Research · United States
Last price 38.51 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.18B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Details
| Name | Castle Biosciences, Inc. |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Employees | 1002 |
| Founded | 2007 |
| Ipo Date | 2019-07-25 |
| Ceo | Derek Maetzold |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 16.00 |
| Isin | US14843C1053 |
| Cusip | 14843C105 |
| Cik | 1447362 |
| Sic | 8071 |
Key executives
| Name | Title |
|---|---|
| Derek J. Maetzold | Founder, Chief Executive Officer, President and Director |
| Frank Stokes | Chief Financial Officer and Treasurer |
| Kristen M. Oelschlager R.N. | Chief Operating Officer |
| Tobin W. Juvenal | Chief Commercial Officer |
| Camilla Zuckero | Vice President of Investor Relations and Corporate Affairs |
| Kevin Doman | Senior Vice President of Sales |
| Dr. Jay Braxton Pharm.D. | Senior Vice President of Marketing |
| Keli Greenberg | Vice President of Human Resources |
| Dr. Matthew Goldberg M.D. | Senior Vice President of Medical |
| Trisha Poteet | Senior Vice President of Clinical Services and Manufacturing Operations |
Contact
| Address | 1500 W. Parkwood Ave, Suite 400, Friendswood, Texas 77546, United States |
| Phone | 866 788 9007 |
| Website | https://castlebiosciences.com |